Gianni Zampieri - Vifor Pharma CEO
CEO
Dr. Gianni Zampieri is Member of the Board of Directors of Vifor Pharma Ltd. since May 2017. He was Member of the Executive Board at Galenica Ltd. since 2002. He is head of Pharma Operations at the company. He was Chief Executive Officer at OM Pharma from 2009 to 2010, Vice CEO of Vifor Pharma since 2011 and Head of Pharma Operations since 2012. He acted as Head of Industrial Operations at Vifor Pharma from 2008 to 2012. He held positions at Roche, Sandoz and Novartis in Strategic Planning before joining the Company group in 1996. In 1997, he became Chief Executive Officer of Vifor in 1997. He graduated from Eidgenoessische Technische Hochschule Zuerich with a Doctorate in Philosophy degree in Natural Sciences and completed Senior Executive Program at Stanford University. He was also Member of the Board of Directors of ECSA Group. since 2017.
| Age | 61 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Phone | 41 58 851 80 00 |
| Web | https://www.viforpharma.com |
Vifor Pharma Management Efficiency
The company has return on total asset (ROA) of 4.6 % which means that it generated a profit of $4.6 on every $100 spent on assets. This is normal as compared to the sector avarege. Similarly, it shows a return on equity (ROE) of 6.65 %, meaning that it generated $6.65 on every $100 dollars invested by stockholders. Vifor Pharma's management efficiency ratios could be used to measure how well Vifor Pharma manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 587.5 M in total debt with debt to equity ratio (D/E) of 0.15, which may suggest the company is not taking enough advantage from borrowing. Vifor Pharma AG has a current ratio of 1.87, which is within standard range for the sector. Debt can assist Vifor Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Vifor Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vifor Pharma AG sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vifor to invest in growth at high rates of return. When we think about Vifor Pharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 11 records | CEO Age | ||
| Sergio Cinerari | Dow Inc | N/A | |
| Ashish Khandpur | Avient Corp | 56 | |
| James Rourke | The Mosaic | 54 | |
| David Overall | Dow Inc | N/A | |
| Daniel OBrien | Flexible Solutions Internationa | 67 | |
| Jon Isaac | Live Ventures | 41 | |
| D Nelson | Dow Inc | N/A | |
| Michael Miller | Dow Inc | N/A | |
| B Petersen | Dow Inc | N/A | |
| James ORourke | The Mosaic | 60 | |
| Grant Fenn | Dow Inc | 52 | |
Management Performance
Vifor Pharma AG Leadership Team
Elected by the shareholders, the Vifor Pharma's board of directors comprises two types of representatives: Vifor Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vifor. The board's role is to monitor Vifor Pharma's management team and ensure that shareholders' interests are well served. Vifor Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vifor Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marc Garidel, member of Board of Director | ||
| David Bevan, CEO Vifor Fresenius Medical Care Renal Pharma Ltd., Member of the Executive Committee | ||
| Daniela BosshardtHengartner, Member of the Board of Directors | ||
| Sue Mahony, Member of the Board of Directors | ||
| Sylvie Gregoire, Director | ||
| Stefan Schulze, President of the Executive Committee, COO | ||
| Christoph Springer, Head of Global Business Development, Member of the Executive Committee | ||
| Hans Frick, Member of the Board of Directors | ||
| Etienne Jornod, Executive Chairman, Chairman of Governane and Nomination Committee, Chairman of Swiss Healthcare Committee and Member of Scientific and Pharma Committee | ||
| Joerg Kneubuehler, Member of the Corporate Executive Committee, CFO | ||
| Stefano Pessina, Member of the Board of Directors | ||
| Michael Puri, Senior Vice President & Head of Global Human Resources, Member of the Executive Committee | ||
| This Schneider, Member of the Board of Directors | ||
| Julien Vignot, Head of Investor Relations | ||
| Scott Garland, President Relypsa, Member of the Executive Committee | ||
| Michel Burnier, Member of the Board of Directors | ||
| Jacques Theurillat, Member of the Board of Directors | ||
| Soeren Tulstrup, Member of the Corporate Executive Committee | ||
| Felix Burkhard, Member of the Corporate Executive Committee | ||
| Gianni Zampieri, Head of Pharma Operations and Vice-CEO of Vifor Pharma | ||
| JeanClaude Clemencon, Member of the Corporate Executive Committee | ||
| Dario Eklund, Chief Commercial Officer, Member of the Executive Committee | ||
| Kim Stratton, Member of the Board of Directors | ||
| Colin Bond, CFO, Member of the Executive Committee | ||
| Romeo Cerutti, member of Board of Directors | ||
| Fritz Hirsbrunner, Head of Investor Relations, Director, Member of Audit and Risk Committee and Member of Swiss Healthcare Committee |
Vifor Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Vifor Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 6.65 | |||
| Return On Asset | 4.6 | |||
| Profit Margin | 7.97 % | |||
| Operating Margin | 20.94 % | |||
| Current Valuation | 11.98 B | |||
| Shares Outstanding | 64.86 M | |||
| Shares Owned By Insiders | 0.06 % | |||
| Shares Owned By Institutions | 26.05 % | |||
| Price To Earning | 29.90 X | |||
| Price To Book | 3.29 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Vifor Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Vifor Pharma's short interest history, or implied volatility extrapolated from Vifor Pharma options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Vifor Pharma AG information on this page should be used as a complementary analysis to other Vifor Pharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Vifor Pink Sheet
If you are still planning to invest in Vifor Pharma AG check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vifor Pharma's history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |